Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2024 18:35 ET | Source: Zealand Pharma

Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion

Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion...
June 25, 2024 14:43 ET | Source: Zealand Pharma

Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion

Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7...
June 25, 2024 11:02 ET | Source: Zealand Pharma

Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion

Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR...
June 20, 2024 11:37 ET | Source: Zealand Pharma

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide ...
June 13, 2024 11:00 ET | Source: Zealand Pharma

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Company announcement – No. 31 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 13, 2024 – Zealand Pharma A/S (“Zealand”)...
June 07, 2024 04:38 ET | Source: Zealand Pharma

Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Company announcement - No. 30 / 2024 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of...
June 06, 2024 06:29 ET | Source: Zealand Pharma

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

Company announcement - No. 29 / 2024 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL Copenhagen, Denmark,...
May 31, 2024 10:03 ET | Source: Zealand Pharma

Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency

Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency ...
May 29, 2024 11:10 ET | Source: Zealand Pharma

Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

Press release – No. 5 / 2024 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no....
May 29, 2024 07:32 ET | Source: Zealand Pharma

Zealand Pharma major shareholder announcement: Polar Capital

Company announcement – No. 28 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 29 May 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50...